Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Neurocrine

Dow Jones Sells Off After Jobs Data, Key Economic Data; OPEC Meeting On Tap

The Dow Jones Industrial Average sold off 300 points Wednesday after a stronger-than-expected ADP employment report.

Investors Business Daily

Dow Jones Surges 600 Points As Treasury Yields Tumble; Apple, Tesla Rally

The Dow Jones Industrial Average surged 600 points Tuesday, as the 10-year Treasury yield continues to tumble. Apple and Tesla rallied.

Investors Business Daily

Dow Jones Rises Ahead Of Powell Speech; 10-Year Treasury Yield Briefly Tops 4%

The Dow Jones Industrial Average rose Wednesday, ahead of Fed chief Powell's speech, struggling to avoid a seventh straight decline.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

The Market Slumped Last Week; Why IBD Stock Of The Day Neurocrine Biosciences Didn't

Neurocrine Biosciences is the IBD Stock Of The Day as market uncertainty shakes plenty leading of equities — but not NBIX stock.

Investors Business Daily

Dow Jones Continues To Fall As Stock Market Correction Worsens; Treasury Yields Surge

The Dow Jones Industrial Average dropped Monday, as the stock market correction worsened. The 10-year Treasury yield surged to new highs.

Investors Business Daily

S&P 500 Giant Leads 5 Stocks Showing Strength In Bear Market

S&P 500 giant Eli Lilly leads five medical stocks setting up and showing relative strength in the ongoing bear market.

Investors Business Daily

Dow Jones Sells Off Ahead Of Powell Comments As Recession Fears Mount

The Dow Jones Industrial Average sold off Friday ahead of Fed chief Powell's comments at a Federal Reserve event in Washington D.C.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Dow Jones Drops After Fed-Fueled Market Sell-Off; Treasury Yields Surge

The Dow Jones Industrial Average dropped Thursday, threatening to add to Wednesday's Fed-fueled stock market sell-off.

Investors Business Daily

IBD 50 Stocks To Watch: Biotech Leader Neurocrine Biosciences Eyes New Buy Point

Among the top stocks to watch today's stock market, biotech leader Neurocrine Biosciences is nearing a new buy point.

Investors Business Daily

Leading Welsh life sciences company Diurnal in £48m takeover by US firm

The board of Diurnal have recommended the takeover bid from Neurocrine

Birmingham Post

S&P 500 Dividend Standout Leads 5 Resilient Stocks Near Buy Points As Fed Looms

S&P 500 dividend standout Devon Energy leads this weekend's watch list of stocks near buy points in a tough market.

Investors Business Daily

Neurocrine Leads 5 Stocks To Watch In Sickly Market

Neurocrine Biosciences leads five medical stocks near key support levels as the health care sector shows resilience in a sickly market.

Investors Business Daily

How IBD Stock Of The Day Neurocrine Bio Shrugged Off A High-Profile Failure

Neurocrine is shrugging off market woes, buoyed by movement drug Ingrezza and NBIX stock investors' hope for its pipeline.

Investors Business Daily

Neurocrine Shelves A Closely Watched Drug, But Stock Upbeat On Quarterly Win

Neurocrine Biosciences said Thursday its essential tremor study didn't pan out, and it shuttered the program. But NBIX stock jumped Friday.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Can IBD Stock Of The Day Neurocrine Biosciences Leapfrog Rivals For A $13 Billion Shot?

Neurocrine is the IBD Stock Of The Day. The biotech stock is approaching two potential entries as the movement disorder space heats up.

Benzinga

Why Neurocrine Biosciences Are Trading Higher Today?

Neurocrine Biosciences Inc (NASDAQ: NBIX) reported

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.